Clinical trials: Acute Treatment of Migraine
Migraine
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
- Trial name
- NCT03670810
- Testing
- Lasmiditan
- Where
- 141 sites in United States, Austria and 15 more
- Volunteers
- 1,633 people
- Sponsor
- Eli Lilly and Company
Migraine, Headache
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
The purpose of this study is to determine whether a fixed-dose combination of naratriptan + naproxen is effective compared each monotherapy for the acute treatment of migraine.
- Trial name
- Atenéia (NCT01390324)
- Testing
- Fixed-dose combination of naratriptan+naproxen, Naratriptan, Naproxen
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Migraine
A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache
The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) 12.5 milligram tablets compared with placebo for the acute treatment of migraine headache at the earliest onset of headache…
- Trial name
- NCT00210509
- Testing
- almotriptan malate
- Volunteers
- 378 people
- Sponsor
- Janssen-Ortho LLC
Migraine
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
- Trial name
- UBR Prodrome (NCT04492020)
- Testing
- Ubrogepant 100 mg
- Where
- 73 sites in United States
- Volunteers
- 518 people
- Sponsor
- AbbVie
Migraine
Real-world Data Analysis of REN Treatment in Migraine Patients
Data analysis concerning four sets of metrics: A. Per-treatment patterns of REN use as a standalone treatment vs. in combination with medications. B.
- Trial name
- NCT04992897
- Testing
- Remote Electrical Neuromodulation (REN)
- Where
- 2 sites in United States, Israel
- Volunteers
- 12,151 people
- Sponsor
- Theranica
Migraine
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.
- Trial name
- NCT05550207
- Testing
- AXS-07 (meloxicam-rizatriptan)
- Where
- 31 sites in United States
- Volunteers
- 100 people
- Sponsor
- Axsome Therapeutics, Inc.
Acute Migraine
Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine
This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.
- Trial name
- Zotrip (NCT02745392)
- Testing
- ZP-Zolmitriptan
- Where
- 36 sites in United States
- Volunteers
- 365 people
- Sponsor
- Zosano Pharma Corporation
Migraine Headache
Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine
Randomized, sham-controlled, double-blind study for acute migraine attacks. Randomized to active treatment and sham treatment arms for the first treatment. Optional second active treatment.
- Trial name
- NCT04584762
- Testing
- Automated Variable Pressure Insufflation
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Nocira, LLC
Migraine
A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine
The purpose of this study is: 1. To compare the efficacy of a single dose of Frovatriptan 2.5 mg with that of placebo in acute treatment of up to one migraine attract 2. To assess recurrence rate between two group 3.
- Trial name
- NCT00821483
- Testing
- Frovatriptan
- Volunteers
- 298 people
- Sponsor
- SK Chemicals Co., Ltd.
Migraine, Acute
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)
This Clinical Trial evaluates the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents.
- Trial name
- NCT01001234
- Testing
- rizatriptan
- Volunteers
- 1,382 people
- Sponsor
- Organon and Co
Migraine Disorders
Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment
The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation.
- Trial name
- NCT00883051
- Testing
- Lasmiditan
- Where
- 39 sites in Belgium, Finland and 3 more
- Volunteers
- 512 people
- Sponsor
- Eli Lilly and Company
Migraine
An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- COURAGE II (NCT05653986)
- Where
- United States
- Volunteers
- 391 people
- Sponsor
- AbbVie
Acute Treatment of Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
- Trial name
- NCT04743141
- Testing
- Rimegepant (PF-07899801)
- Where
- 124 sites in United States, Poland and 1 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Migraine Headache
MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)
A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.
- Trial name
- NCT00897104
- Testing
- rizatriptan benzoate (MK0462), Comparator: sumatriptan
- Volunteers
- 933 people
- Sponsor
- Organon and Co
Migraine Headache
MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo.
- Trial name
- NCT00897949
- Testing
- rizatriptan benzoate (MK0462)
- Volunteers
- 1,473 people
- Sponsor
- Organon and Co
Migraine
Maximizing Outcomes in Treating Acute Migraine
AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults.
- Trial name
- MOMENTUM (NCT03896009)
- Testing
- AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan
- Where
- 85 sites in United States
- Volunteers
- 1,594 people
- Sponsor
- Axsome Therapeutics, Inc.
Migraine
A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
This study will provide additional efficacy data for rizatriptan when used for an acute migraine attack in patients already taking topiramate for migraine prophylaxis.
- Trial name
- NCT00812006
- Testing
- rizatriptan benzoate
- Volunteers
- 108 people
- Sponsor
- Organon and Co
Migraine
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
- Trial name
- NCT06603623
- Testing
- BHV-2100
- Where
- 60 sites in United States
- Volunteers
- 647 people
- Sponsor
- Biohaven Therapeutics Ltd.
Migraine
Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy
To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy
- Trial name
- NCT00632385
- Testing
- Eletriptan
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it.
- Trial name
- NCT07646613
- Testing
- ASY202
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Aspeya, Inc.